APO Research
Talk to an analyst

APO RESEARCH · REPORT

Adrenocortical Carcinoma Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Adrenocortical Carcinoma Drugs Market Outlook and Growth Opportunities 2026

22 December 2025192 pages

Choose your research edition.

Industry ResearchAdrenocortical Carcinoma Drugs Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Adrenocortical Carcinoma Drugs Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Adrenocortical Carcinoma Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Adrenocortical Carcinoma Drugs Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Adrenocortical Carcinoma Drugs Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Adrenocortical Carcinoma Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Adrenocortical Carcinoma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Adrenocortical Carcinoma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Adrenocortical Carcinoma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Adrenocortical Carcinoma Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Adrenocortical Carcinoma Drugs market include Teva Pharmaceutical Industries Ltd., Eli Lilly and Co., Bristol-Myers Squibb Co., Progenics Pharmaceuticals Inc. and Laboratoire HRA Pharma SAS, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Adrenocortical Carcinoma Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Adrenocortical Carcinoma Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Adrenocortical Carcinoma Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Adrenocortical Carcinoma Drugs market.

Adrenocortical Carcinoma Drugs Segment by Company

Teva Pharmaceutical Industries Ltd.

Eli Lilly and Co.

Bristol-Myers Squibb Co.

Progenics Pharmaceuticals Inc.

Laboratoire HRA Pharma SAS

Adrenocortical Carcinoma Drugs Segment by Type

Chemotherapy

Targeted therapy

Adrenocortical Carcinoma Drugs Segment by Application

Research institute

Hospital

Clinic

Other

Adrenocortical Carcinoma Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Adrenocortical Carcinoma Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Adrenocortical Carcinoma Drugs key companies, revenue, market share, and recent developments.

3. To split the Adrenocortical Carcinoma Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Adrenocortical Carcinoma Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Adrenocortical Carcinoma Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Adrenocortical Carcinoma Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Adrenocortical Carcinoma Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Adrenocortical Carcinoma Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Adrenocortical Carcinoma Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Adrenocortical Carcinoma Drugs industry.

Chapter 3: Detailed analysis of Adrenocortical Carcinoma Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Adrenocortical Carcinoma Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Adrenocortical Carcinoma Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Adrenocortical Carcinoma Drugs Industry Trends Table 2. Adrenocortical Carcinoma Drugs Industry Drivers Table 3. Adrenocortical Carcinoma Drugs Industry Opportunities and Challenges Table 4. Adrenocortical Carcinoma Drugs Industry Restraints Table 5. Global Adrenocortical Carcinoma Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Adrenocortical Carcinoma Drugs Revenue Share by Company (2021-2026) Table 7. Global Adrenocortical Carcinoma Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Adrenocortical Carcinoma Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Adrenocortical Carcinoma Drugs Company, Product Type & Application Table 10. Global Adrenocortical Carcinoma Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Adrenocortical Carcinoma Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Chemotherapy Table 15. Significant Companies of Targeted therapy Table 16. Global Adrenocortical Carcinoma Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Adrenocortical Carcinoma Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Adrenocortical Carcinoma Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Adrenocortical Carcinoma Drugs Sales Value Share by Type (2021-2026) Table 20. Global Adrenocortical Carcinoma Drugs Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Research institute Table 22. Significant Companies of Hospital Table 23. Significant Companies of Clinic Table 24. Significant Companies of Other Table 25. Global Adrenocortical Carcinoma Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Adrenocortical Carcinoma Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Adrenocortical Carcinoma Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Adrenocortical Carcinoma Drugs Sales Value Share by Application (2021-2026) Table 29. Global Adrenocortical Carcinoma Drugs Sales Value Share by Application (2027-2032) Table 30. Global Adrenocortical Carcinoma Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Adrenocortical Carcinoma Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Adrenocortical Carcinoma Drugs Sales Value Share by Region (2021-2026) Table 33. Global Adrenocortical Carcinoma Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Adrenocortical Carcinoma Drugs Sales Value Share by Region (2027-2032) Table 35. Global Adrenocortical Carcinoma Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Adrenocortical Carcinoma Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Adrenocortical Carcinoma Drugs Sales Value Market Share by Country (2021-2026) Table 38. Global Adrenocortical Carcinoma Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Adrenocortical Carcinoma Drugs Sales Value Market Share by Country (2027-2032) Table 40. Teva Pharmaceutical Industries Ltd. Company Information Table 41. Teva Pharmaceutical Industries Ltd. Business Overview Table 42. Teva Pharmaceutical Industries Ltd. Adrenocortical Carcinoma Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Teva Pharmaceutical Industries Ltd. Adrenocortical Carcinoma Drugs Product Portfolio Table 44. Teva Pharmaceutical Industries Ltd. Recent Development Table 45. Eli Lilly and Co. Company Information Table 46. Eli Lilly and Co. Business Overview Table 47. Eli Lilly and Co. Adrenocortical Carcinoma Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Eli Lilly and Co. Adrenocortical Carcinoma Drugs Product Portfolio Table 49. Eli Lilly and Co. Recent Development Table 50. Bristol-Myers Squibb Co. Company Information Table 51. Bristol-Myers Squibb Co. Business Overview Table 52. Bristol-Myers Squibb Co. Adrenocortical Carcinoma Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Bristol-Myers Squibb Co. Adrenocortical Carcinoma Drugs Product Portfolio Table 54. Bristol-Myers Squibb Co. Recent Development Table 55. Progenics Pharmaceuticals Inc. Company Information Table 56. Progenics Pharmaceuticals Inc. Business Overview Table 57. Progenics Pharmaceuticals Inc. Adrenocortical Carcinoma Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Progenics Pharmaceuticals Inc. Adrenocortical Carcinoma Drugs Product Portfolio Table 59. Progenics Pharmaceuticals Inc. Recent Development Table 60. Laboratoire HRA Pharma SAS Company Information Table 61. Laboratoire HRA Pharma SAS Business Overview Table 62. Laboratoire HRA Pharma SAS Adrenocortical Carcinoma Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Laboratoire HRA Pharma SAS Adrenocortical Carcinoma Drugs Product Portfolio Table 64. Laboratoire HRA Pharma SAS Recent Development Table 65. Research Programs/Design for This Report Table 66. Authors List of This Report Table 67. Secondary Sources Table 68. Primary Sources List of Figures Figure 1. Adrenocortical Carcinoma Drugs Product Image Figure 2. Global Adrenocortical Carcinoma Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Adrenocortical Carcinoma Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Adrenocortical Carcinoma Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Chemotherapy Image Figure 8. Targeted therapy Image Figure 9. Global Adrenocortical Carcinoma Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Adrenocortical Carcinoma Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Adrenocortical Carcinoma Drugs Sales Value Share by Type (2021-2032) Figure 12. Research institute Image Figure 13. Hospital Image Figure 14. Clinic Image Figure 15. Other Image Figure 16. Global Adrenocortical Carcinoma Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Adrenocortical Carcinoma Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Adrenocortical Carcinoma Drugs Sales Value Share by Application (2021-2032) Figure 19. Global Adrenocortical Carcinoma Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Adrenocortical Carcinoma Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Adrenocortical Carcinoma Drugs Sales Value (2021-2032) & (US$ Million) Figure 22. North America Adrenocortical Carcinoma Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Adrenocortical Carcinoma Drugs Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Adrenocortical Carcinoma Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Adrenocortical Carcinoma Drugs Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Adrenocortical Carcinoma Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Adrenocortical Carcinoma Drugs Sales Value (2021-2032) & (US$ Million) Figure 28. South America Adrenocortical Carcinoma Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Adrenocortical Carcinoma Drugs Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Adrenocortical Carcinoma Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Chemotherapy
  • Targeted therapy
Applications
  • Research institute
  • Hospital
  • Clinic
  • Other
Companies covered
  • Teva Pharmaceutical Industries Ltd.
  • Eli Lilly and Co.
  • Bristol-Myers Squibb Co.
  • Progenics Pharmaceuticals Inc.
  • Laboratoire HRA Pharma SAS

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Adrenocortical Carcinoma Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Adrenocortical Carcinoma Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Adrenocortical Carcinoma Drugs Market Dynamics
  1. 2.1 Adrenocortical Carcinoma Drugs Industry Trends
  2. 2.2 Adrenocortical Carcinoma Drugs Industry Drivers
  3. 2.3 Adrenocortical Carcinoma Drugs Industry Opportunities and Challenges
  4. 2.4 Adrenocortical Carcinoma Drugs Industry Restraints
3 Adrenocortical Carcinoma Drugs Market by Company
  1. 3.1 Global Adrenocortical Carcinoma Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Adrenocortical Carcinoma Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Adrenocortical Carcinoma Drugs Company Ranking (2024-2026)
  4. 3.4 Global Adrenocortical Carcinoma Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Adrenocortical Carcinoma Drugs Company Product Type and Application
  6. 3.6 Global Adrenocortical Carcinoma Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Adrenocortical Carcinoma Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Adrenocortical Carcinoma Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Adrenocortical Carcinoma Drugs Market by Type
  1. 4.1 Adrenocortical Carcinoma Drugs Type Introduction
  2. 4.1.1 Chemotherapy
  3. 4.1.2 Targeted therapy
  4. 4.2 Global Adrenocortical Carcinoma Drugs Sales Value by Type
  5. 4.2.1 Global Adrenocortical Carcinoma Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Adrenocortical Carcinoma Drugs Sales Value by Type (2021-2032)
  7. 4.2.3 Global Adrenocortical Carcinoma Drugs Sales Value Share by Type (2021-2032)
5 Adrenocortical Carcinoma Drugs Market by Application
  1. 5.1 Adrenocortical Carcinoma Drugs Application Introduction
  2. 5.1.1 Research institute
  3. 5.1.2 Hospital
  4. 5.1.3 Clinic
  5. 5.1.4 Other
  6. 5.2 Global Adrenocortical Carcinoma Drugs Sales Value by Application
  7. 5.2.1 Global Adrenocortical Carcinoma Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Adrenocortical Carcinoma Drugs Sales Value by Application (2021-2032)
  9. 5.2.3 Global Adrenocortical Carcinoma Drugs Sales Value Share by Application (2021-2032)
6 Adrenocortical Carcinoma Drugs Regional Value Analysis
  1. 6.1 Global Adrenocortical Carcinoma Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Adrenocortical Carcinoma Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Adrenocortical Carcinoma Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Adrenocortical Carcinoma Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Adrenocortical Carcinoma Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Adrenocortical Carcinoma Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Adrenocortical Carcinoma Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Adrenocortical Carcinoma Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Adrenocortical Carcinoma Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Adrenocortical Carcinoma Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Adrenocortical Carcinoma Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Adrenocortical Carcinoma Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Adrenocortical Carcinoma Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Adrenocortical Carcinoma Drugs Sales Value Share by Country, 2025 VS 2032
7 Adrenocortical Carcinoma Drugs Country-level Value Analysis
  1. 7.1 Global Adrenocortical Carcinoma Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Adrenocortical Carcinoma Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Adrenocortical Carcinoma Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Adrenocortical Carcinoma Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Adrenocortical Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Adrenocortical Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Adrenocortical Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical Industries Ltd.
  2. 8.1.1 Teva Pharmaceutical Industries Ltd. Company Information
  3. 8.1.2 Teva Pharmaceutical Industries Ltd. Business Overview
  4. 8.1.3 Teva Pharmaceutical Industries Ltd. Adrenocortical Carcinoma Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical Industries Ltd. Adrenocortical Carcinoma Drugs Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  7. 8.2 Eli Lilly and Co.
  8. 8.2.1 Eli Lilly and Co. Company Information
  9. 8.2.2 Eli Lilly and Co. Business Overview
  10. 8.2.3 Eli Lilly and Co. Adrenocortical Carcinoma Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eli Lilly and Co. Adrenocortical Carcinoma Drugs Product Portfolio
  12. 8.2.5 Eli Lilly and Co. Recent Developments
  13. 8.3 Bristol-Myers Squibb Co.
  14. 8.3.1 Bristol-Myers Squibb Co. Company Information
  15. 8.3.2 Bristol-Myers Squibb Co. Business Overview
  16. 8.3.3 Bristol-Myers Squibb Co. Adrenocortical Carcinoma Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bristol-Myers Squibb Co. Adrenocortical Carcinoma Drugs Product Portfolio
  18. 8.3.5 Bristol-Myers Squibb Co. Recent Developments
  19. 8.4 Progenics Pharmaceuticals Inc.
  20. 8.4.1 Progenics Pharmaceuticals Inc. Company Information
  21. 8.4.2 Progenics Pharmaceuticals Inc. Business Overview
  22. 8.4.3 Progenics Pharmaceuticals Inc. Adrenocortical Carcinoma Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Progenics Pharmaceuticals Inc. Adrenocortical Carcinoma Drugs Product Portfolio
  24. 8.4.5 Progenics Pharmaceuticals Inc. Recent Developments
  25. 8.5 Laboratoire HRA Pharma SAS
  26. 8.5.1 Laboratoire HRA Pharma SAS Company Information
  27. 8.5.2 Laboratoire HRA Pharma SAS Business Overview
  28. 8.5.3 Laboratoire HRA Pharma SAS Adrenocortical Carcinoma Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Laboratoire HRA Pharma SAS Adrenocortical Carcinoma Drugs Product Portfolio
  30. 8.5.5 Laboratoire HRA Pharma SAS Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst